The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases. The trial will test three
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tol
Introduction Regulatory T cells (Tregs) have attracted attention as a novel therapeutic target to augment the clinical efficacy of immunotherapy. We conducted phase Ia and Ib trials to examine the saf
aRhesus monkeys 5 animals per group.bVaccines are mixtures of vectors expressing the individual antigens PkCSP, PkAMA1, PkSSP2, and PkMSP1.cRecombinant VRP, 5×107 IU/dose each antigen.dRecombinant Ad5